Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

BACKGROUND & AIMS: While fibrosis stage predicts liver‐associated mortality, cardiovascular disease (CVD) is still the major overall cause of mortality in patients with NASH. Novel NASH drugs should thus ideally reduce both liver fibrosis and CVD. Icosabutate is a semi‐synthetic, liver‐targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Stokman, Geurt, van den Hoek, Anita M., Denker Thorbekk, Ditte, Pieterman, Elsbet J., Skovgård Veidal, Sanne, Basta, Brittany, Iruarrizaga‐Lejarreta, Marta, van der Hoorn, José W., Verschuren, Lars, Berbée, Jimmy F. P., Rensen, Patrick C. N., Skjæret, Tore, Alonso, Cristina, Feigh, Michael, Kastelein, John J. P., Friedman, Scott L., Princen, Hans M. G., Fraser, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Experimental Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702170/
https://www.ncbi.nlm.nih.gov/pubmed/32841505
http://dx.doi.org/10.1111/liv.14643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702170/
https://www.ncbi.nlm.nih.gov/pubmed/32841505
http://dx.doi.org/10.1111/liv.14643

Ejemplares similares